Evidence map›Paper›PMID 32431267›Full record

ArticleThe American journal of tropical medicine and hygiene2020

The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of

Junko Takata, Paul Sondo, Georgina S Humphreys, Rebekah Burrow, Brittany Maguire, Mohammad S Hossain, Debashish Das, Robert J Commons, Ric N Price, Philippe J Guerin

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Mapping the prevalence of molecular markers ofmedRxiv : the preprint server for health sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.International journal for parasitology. Drugs and drug resistance · 2021
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junko Takata1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Paul Sondo1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Georgina S Humphreys1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Rebekah Burrow1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Brittany Maguire2Infectious Diseases Data Observatory (IDDO), Oxford, United Kingdom.
Mohammad S Hossain1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Debashish Das1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Robert J Commons1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Ric N Price1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
Philippe J Guerin1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parasite resistance to antimalarial drugs poses a serious threat to malaria control. The WorldWide Antimalarial Resistance Network (WWARN) aims to provide a collaborative platform to support the global malaria research effort. Here, we describe the "WWARN clinical trials publication library," an open-access, up-to-date resource to streamline the synthesis of antimalarial safety and efficacy data. A series of iteratively refined database searches were conducted to identify prospective clinical trials assessing antimalarial drug efficacy with at least 28 days of follow-up. Of approximately 45,000 articles screened, 1,221 trials published between 1946 and 2018 were identified, representing 2,339 treatment arms and 323,819 patients. In trials from endemic locations, 75.7% (787/1,040) recruited patients with

Indexed as

Drug ResistanceAntimalarialsClinical Trials as TopicDatabases, BibliographicDatabases, FactualDrug Therapy, CombinationHumansMalariaMalaria, FalciparumMalaria, VivaxPlasmodiumPlasmodium falciparumPlasmodium knowlesiPlasmodium malariaePlasmodium ovalePlasmodium vivaxAntimalarials

Identifiers

PMID32431267
PMCPMC7356478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.